This Article Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Felmeden, D. C Articles by Lip, G. Y. Search for Related Content PubMed PubMed Citation Articles by Felmeden, D. C Articles by Lip, G. Y. Social Bookmarking                         What's this?

The renin-angiotensin-aldosterone system and fibrinolysis

Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham UK

Gregory YH Lip

Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham UK, G.Y.H.LIP{at}bham.ac.uk

Key Words: fibrinolysis • thrombosis • RAAS

References

• Alderman MH, Madhavan S., Ooi WL, Cohen H., Sealey JE, Laragh JH Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991;324(16):1098-104.[Abstract]
• Brunner HR, Laragh JH, Baer L. et al. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 1972; 286(9):441-9.[Web of Science][Medline] [Order article via Infotrieve]
• Pitt B., Poole-Wilson PA, Segal R. et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 335(9215): 1582-7.
• Vaughan DE, Rouleau JL, Ridker PM, Arnold JM, Menapace FJ, Pfeffer MA Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators. Circulation 1997; 96(2):442-7.[Abstract/Free Full Text]
• Pitt B., Segal R., Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349(9054):747-52.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Vaughan DE Fibrinolytic balance, the renin-angiotensin system and atherosclerotic disease. Eur Heart J1998; 19 Suppl G:G9-12.[Web of Science][Medline] [Order article via Infotrieve]
• Hamsten A., Wiman B., de Faire U., Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313(25):1557-63.[Abstract]
• Jansson JH, Boman K., Nilsson TK Enalapril-related changes in the fibrinolytic system in survivors of myocardial infarction. Eur J Clin Pharmacol 1993; 44(5):485-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Hamsten A., de Faire U., Walldius G. et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2(8549):3-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Sjoland H., Eitzman DT, Gordon D., Westrick R., Nabel EG, Ginsburg D. Atherosclerosis progression in LDL receptor deficient and apolipoprotein E-deficient mice is independent of genetic alterations in plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol 2000; 20: 846-52.[Abstract/Free Full Text]
• Saksela O., Rifkin DB Cell-associated plasminogen activation: regulation and physiological functions. Annu Rev Cell Biol 1988; 4:93-126.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Lupu F., Heim DA, Bachmann F., Hurni M., Kakkar VV, Kruithof EK Plasminogen activator expression in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1995; 15(9):1444-55.[Abstract/Free Full Text]
• Kinlay S., Selwyn AP, Libby P., Ganz P. Inflammation, the endothelium, and the acute coronary syndromes. J Cardiovasc Pharmacol 1998; 32 Suppl 3:S62-S66.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Collen D. On the regulation and control of fibrinolysis. Edward Kowalski Memorial Lecture. Thromb Haemost 1980; 43:77-89.[Web of Science][Medline] [Order article via Infotrieve]
• Schneiderman J., Sawdey MS, Keeton MR et al. Increased type-1 plasminogen activator inhibitor gene expression in atherosclerotic plaques of human arteries. Proc Natl Acad Sci USA 192; 89:6998-7002.
• Kerins DM, Hao O., Vaughan DE Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest 1995; 96:2515-20.[Web of Science][Medline] [Order article via Infotrieve]
• Ridker PM, Gaboury CL, Conlin PR, Seely EW,Williams GH, Vaughan DE Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin- angiotensin system and fibrinolytic function. Circulation 1993; 87(6):1969-73.[Abstract/Free Full Text]
• Vaughan DE, Lazos S.,Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-type1 in cultured endothelial cells.A potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995; 95(3):995-1001.[Web of Science][Medline] [Order article via Infotrieve]
• Juhan-Vague I., Pyke SDM, Alessi MC, Jespersen J., Haverkate F., Thompson SG Fibrinolytic factors and risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation 1996; 94(9):2057-63.[Abstract/Free Full Text]
• Brown NJ, Agirbasli MA, Williams GH, Litchfield WR, Vaughan DE Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Hypertension 1998; 32(6):965-71.[Abstract/Free Full Text]
• Matsubara Y., Hayakawa T., Tsuda T. et al. Angiotensin converting enzyme insertion/deletion polymorphism is associated with plasma antigen levels of plasminogen activator inhibitor-1 in healthy Japanese population. Blood Coagul Fibrinolysis 2000;11(2):115-20.[Web of Science][Medline] [Order article via Infotrieve]
• Brown NJ, Ryder D., Gainer JV, Morrow JD, Nadeau J. Differential effects of Angiotensin Converting Enzyme inhibitors on the vasopressor and prostacyclin responses to bradykinin. J Pharmacol Exp Ther 1996; 279:703-12.[Abstract/Free Full Text]
• van Leeuwen RT, Kol A.,Andreotti F., Kluft C., MaseriA, Sperti G.Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells. Circulation 1994; 90(1):362-8.[Abstract/Free Full Text]
• Brown NJ, Nadeau J., Vaughan DE Selective stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin. Thromb Haemost 1997; 77(3):522-5.[Web of Science][Medline] [Order article via Infotrieve]
• Alessi MC, Juhan-Vague I., KooistraT, Declerck PJ, Collen D. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular line Hep G2. Thromb Haemost 1988; 60:491-4.[Web of Science][Medline] [Order article via Infotrieve]
• Vuorinen-Markkola H., Yki-Jarvinen H. Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus. Metabolism 1995; 44(1):85-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Zannad F., Bray-Desboscs L., el Ghawi R., Donner M.,Thibout E., Stoltz JF Effects of lisinopril and hydrochlorothiazide on platelet function and blood rheology in essential hypertension: a randomly allocated double-blind study. J Hypertens 1993; 11(5):559-64.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Erdem Y., Usalan C., Haznedaroglu IC et al. Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension. Am J Hypertens 1999; 12(11 Pt 1):1071-76.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Stanziola L., Greene LJ, Santos RAS. Effect of chronic angiotensin converting enzyme inhibition on angiotensin I and bradykinin metabolism in rats. Am J Hypertens 1999; 12(10 Pt 1):1021-29.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Margaglione M., Cappucci G., d'Addedda M et al. PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis: relation to environmental and genetic determinants.ArteriosclerThromb Vasc Biol 1998; 18(4):562-7.[Abstract/Free Full Text]
• Kim DK, Kim JW, Kim S. et al. Polymorphism of angiotensin converting enzyme gene is associated with circulating levels of plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol 1997; 17(11):3242-7.[Abstract/Free Full Text]
• Goodfield NER, Newby DE, Ludlam CA, Flapan AD Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure. Circulation 1999; 99:2983-5.[Abstract/Free Full Text]
• Katoh M., Egashira K., Mitsui T., Takeshita A., Narita H. Differential effects of imidapril and candesartan cilexetil on plasminogen activator inhibitor-1 expression induced by prolonged inhibition of nitric oxide synthesis in rat hearts. J Cardiovasc Pharmacol 2000; 35(6):932-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Seljeflot I., Moan A., Kjeldsen S., Sandvik E., Arnesen H. Effect of angiotensin II receptor blockade on fibrinolysis during hyperinsulinemia in patients with essential hypertension. Hypertension 1996; 27: 1299-304.[Abstract/Free Full Text]
• Mugellini, A.,Zoppi, A., Corradi L. et al. Effect of trandolapril and losartan on plasma PAI-1 and fibrinogen in hypertensive postmenopausal women. Am J Hypertens 1998; 11: 11A. (Abstract)
• Brown NJ,Agirbasli M., Vaughan DE Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans. Hypertension 1999; 34(2):285-90.[Abstract/Free Full Text]
• The effect of antihypertensive drug treatment on mortality in the presence of resting electrocardiographic abnormalities at baseline: the HDFP experience. The Hypertension Detection and Follow-up Program Cooperative Research Group. Circulation 1984; 70(6):996-1003.[Abstract/Free Full Text]
• Baseline rest electrocardiographic abnormalities, antihypertensive treatment, and mortality in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Am J Cardiol 1985; 55(1):1-15.[CrossRef][Medline] [Order article via Infotrieve]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 1, No. 3, 240-244 (2000)
DOI: 10.3317/jraas.2000.036


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				R. von Kanel and J. E. Dimsdale Hemostatic Alterations in Patients With Obstructive Sleep Apnea and the Implications for Cardiovascular Disease Chest, November 1, 2003; 124(5): 1956 - 1967. [Abstract] [Full Text] [PDF]

This Article Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Felmeden, D. C Articles by Lip, G. Y. Search for Related Content PubMed PubMed Citation Articles by Felmeden, D. C Articles by Lip, G. Y. Social Bookmarking                         What's this?